Posts Tagged ‘GERN’

Stem Cell Stock Analysis

In BUSINESS OF STEM CELLS on September 29, 2009 at 12:32 pm


To see a REAL TIME list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS – REAL TIME

To see a DAY WATCH list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS – DAY WATCH

To see a BASIC list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS – BASIC

To see a SUMMARRY list of these stocks on YAHOO FINANCE click here: STEM CELL STOCKS – SUMMARRY

These are the stocks currently covered:


Changes to this list may occur without notice.  Information provided by YAHOO FINANCE is for information and educational purposes only.  All stock prices and trades should be verified b a certified broker.

thanks to the The Stem Cell Stock List.

Geron Clone? SEC says CellCyte Genetics lied to inflate stock price

In BUSINESS OF STEM CELLS on September 9, 2009 at 7:23 am

SEC: Bothell biotech firm lied to inflate stock price


Federal regulators filed complaints Tuesday against (CellCyte Genetics Corp.) a Bothell-based biotechnology company, saying management of the firm defrauded investors by inflating claims about a stem cell technology it was developing.

In a statement to media, a Securities and Exchange Commission spokesperson alleged that CellCyte Genetics Corp. misled investors into believing the technology was headed for human trials when in fact the company’s product remained in the early stages of development.

SEC officials allege stock promoters hired by CellCyte then spread the false information to investors, driving the stock price to $7.50-a-share before it plummeted back to less than a dime.

The complaints, filed in federal district court in Seattle, allege that in multiple public filings with the SEC and in other investor materials CellCyte falsely claimed it had received U.S. Food and Drug Administration approval to begin human clinical trials with a special stem cell compound to repair the heart, the spokesperson said.

The SEC alleges that CellCyte did not know how to properly formulate the stem cell compound, had never tried experiments with the compound to repair organs and had not satisfied any of the FDA requirements to begin human clinical trials.

In addition to the corporation, the SEC named in the suit CellCyte’s then-Chief Scientific Officer Ronald Berninger, of Mukilteo, who allegedly approved or participated in the drafting of false and misleading statements.

CellCyte and Berninger agreed to a settlement, without admitting or denying the SEC’s allegations, in which they each consented to a permanent injunction, according to the news statement. Berninger also agreed to pay a $50,000 penalty and be barred from serving as an officer or director of a public company for five years.

Speaking Tuesday, CellCyte attorney Steve Fogg noted that the company did not pay a financial penalty and emphasized that the decision to settle with the SEC carried no admittion of guilt. Fogg said the company is no longer pursuing the technology at issue in the complaint.

“Given that they’re moving forward with a separate technology, it just made sense to settle this lawsuit,” said Fogg, adding that “nobody cashed in on CellCyte stock who was an officer or director of CellCyte.”

In a separate action, the SEC has accused ex-CellCyte CEO Gary Reys, of Freeland, of approving the company’s fraudulent SEC filings. Federal regulators are seeking injunctive relief, a monetary penalty and an order barring Reys from serving as an officer or director of a public company.

A few other sources of this info:

SEC Whacks CellCyte Genetics & Bosses
Courthouse News Service – ‎29 minutes ago‎ – SEATTLE (CN)
SEC: Bothell biotech co lied about breakthrough to inflate stock price
KOMO News – Martha Kang – ‎6 hours ago‎ – SEATTLE
SEC accuses CellCyte Genetics, former top execs of fraud
TechFlash – Eric Engleman – ‎8 hours ago‎
SEC Charges CellCyte With Stem Cell Fraud
Xconomy – Luke Timmerman – ‎14 hours ago‎
SEC sues CellCyte, former execs for lying to investors
FierceBiotech – Calisha Myers – ‎14 hours ago‎
SEC accuses CellCyte, execs of fraud
Bizjournals.com – ‎14 hours ago‎
SEC Charges Seattle-Area Biotech Company With Fraudulently Hyping
PharmaLive.com (press release) – ‎15 hours ago‎
BRIEF-US SEC charges CellCyte for fraudulently touting stem cell
Forbes – Julie Vorman – ‎16 hours ago‎
SEC sues CellCyte and its executives
Seattle Times – ‎17 hours ago‎

The Stem Cell Stock Index

In BUSINESS OF STEM CELLS on September 7, 2009 at 8:36 pm


The Stem Cell Stock Index

ACTC.PK 3:59pm $0.15 0.03 20.00%
AFFX 4:00pm $8.55 0.16 1.91%
ASTM 3:59pm $0.43 0.03 7.23%
ATHX 3:58pm $0.98 -0.01 -1.00%
BCLI.OB 3:59pm $0.24 -0.03 -11.11%
BHRT.OB 1:26pm $0.77 -0.01 -1.28%
BIO 4:02pm $87.20 1.05 1.22%
BTIM.OB 3:59pm $3.50 -0.07 -1.96%
CBAI.OB 3:59pm $0.00 0.00 3.45%
CCEL.OB 3:58pm $2.25 0.09 4.17%
CELG 4:00pm $51.74 0.75 1.47%
CUR 4:00pm $1.14 0.04 3.63%
CYTX 4:00pm $3.12 0.13 4.35%
CVM 4:00pm $0.67 0.00 0.00%
DNDN 4:00pm $23.80 0.80 3.48%
GERN 4:00pm $7.21 0.30 4.34%
HTDS.PK 3:59pm $0.01 -0.00 -4.24%
ISCO.OB 3:49pm $0.82 -0.05 -5.75%
KOOL 3:59pm $0.62 -0.02 -3.12%
MCET.OB 3:57pm $0.02 -0.00 -6.00%
NBS 1:55pm $1.84 -0.06 -3.03%
OPXA 3:59pm $1.53 0.04 2.83%
OSIR 4:00pm $12.21 0.69 5.99%
PSTI 3:58pm $1.31 -0.02 -1.50%
RENE.L 11:21am $6.75 1.00 17.39%
SCII.OB 2:41pm $0.04 0.01 16.67%
SCLL.PK 3:55pm $0.00 -0.00 -3.23%
SCLZ.PK 3:22pm $0.03 -0.00 -11.76%
SCTPF.PK 1:36pm $0.12 0.00 2.06%
SSS.V 3:32pm $0.13 -0.01 -7.14%
STEM 4:00pm $1.69 0.04 2.42%
VODG.OB 3:48pm $0.30 0.00 0.00%


Geron Gives Reason for FDA Hold; Shares Rise

In BUSINESS OF STEM CELLS on August 27, 2009 at 1:07 pm

Geron Gives Reason for FDA Hold on Stem-Cell Trial; Shares Rise

By Rob Waters

Aug. 27 (Bloomberg) — Geron Corp. rose as much as 5 percent in Nasdaq trading after saying a hold placed by U.S. regulators on its plan for the first human embryonic stem-cell study was due to “non-proliferative” cysts in test animals.

The Food and Drug Administration cleared Geron in January to test its stem-cell treatment in patients with spinal cord injuries. The company, based in Menlo Park, California, announced the regulatory hold on Aug. 18.

The microscopic cysts seen in an early experiment in a few animals that received the cell-based treatment, GRNOPC1, were found in larger numbers of animals in a recent study. The cysts weren’t linked to complications, the company said in a statement today. A more recent study of rats using a new batch of test chemicals showed no cysts, the company said.

Stephen Brozak, an analyst with WBB Securities LLC in Westfield, New Jersey, said investors would be reassured that the animals didn’t develop a type of tumor known as a teratoma.

“I think it provides people with a reasonable explanation,” Brozak said. “Everybody was afraid of the T- word, teratomas, and it clearly wasn’t that.” Brozak has a “strong buy” rating on the shares.

Geron rose 12 cents, or 1.7 percent, to $7.05 at 11 a.m. New York time in Nasdaq Stock Market composite trading, and traded as high today as $7.28. The shares fell 10 percent after the company announced the FDA’s hold on Aug. 18.

via Geron Gives Reason for FDA Hold on Stem-Cell Trial; Shares Rise – Bloomberg.com.

BrainStorm (BCLI) – Bone Marrow Stem Cell Co. Profile Released

In BUSINESS OF STEM CELLS on August 27, 2009 at 8:42 am

Bone Marrow Stem Cell Company Profile Released

LAS VEGAS, Aug. 27, 2009 (GLOBE NEWSWIRE) — A report addressing one company’s research using human bone marrow stem cells has been released. The report will explore the efforts of BrainStorm (OTCBB:BCLI) and is of interest to investors of leading stem cell equities Geron (Nasdaq:GERN), Osiris Therapeutics (Nasdaq:OSIR), Aastrom Biosciences (Nasdaq:ASTM) and StemCells (Nasdaq:STEM).

From the report: BrainStorm (OTCBB:BCLI) is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient’s own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury.

The adult stem cells are used to create healthy NTF cells which produce and secrete neurotrophic factors, which are essential for the survival and outgrowth of neurons, and may become beneficial in neurodegenerative diseases. Patients treated with the Company’s NurOwn(tm) therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm’s therapy has the potential to cure underlying pathology, rather than simply treat symptoms. BrainStorm’s management and scientific teams are passionately devoted to the Company’s mission: regenerating the mind… in their lifetime.

via SmallCapSentinel.com: Bone Marrow Stem Cell Company Profile Released.


In STEM CELLS IN THE NEWS on August 27, 2009 at 8:15 am
Geron Comments on FDA Hold on Spinal Cord Injury Trial

MENLO PARK, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq:GERN) today provided additional comments on the recent clinical hold on its Spinal Cord Injury IND.

As biologic therapeutics advance in clinical trials, it is common practice to optimize product characteristics, improve manufacturing efficiency and scale, and to test the product in multiple disease models. As part of these ongoing efforts at Geron with respect to GRNOPC1, various animal studies were, and continue to be, performed to characterize the product’s effects in vivo. In previous animal studies of GRNOPC1 using materials that passed release specifications, a very low frequency of injected animals developed microscopic cysts in the regenerating injury site. These cysts were non-proliferative, confined to the injury site, and had no adverse effects on the animals. No animals developed teratomas or any other ectopic structure. Cysts of much larger size appear in the spinal cord scar tissue of up to 50% of patients with spinal cord injury.

A just completed animal study showed a higher frequency of cysts, although their characteristics were similar to the cysts seen in previous studies: non-proliferative, confined to the injury site, smaller than the injury cavity and not associated with adverse clinical outcomes.

As part of our ongoing product improvement efforts, new candidate markers and assays for product release have been identified that are linked with cyst formation across all animal studies in which cysts were found. Importantly, a manufactured lot of GRNOPC1 that was assessed using these markers and assays showed no cysts in another recently concluded animal study in spinal cord injured rats.

We have submitted these data to the FDA and are in discussions with the agency to answer its questions and proceed with the clinical trial. We are committed to the optimization of all our hESC-based products as we improve the manufacturing process and identify improved product release criteria.

Stem Cell Stock Index

In BUSINESS OF STEM CELLS on August 26, 2009 at 9:48 pm

Today the Index Value closed at $4.87, up 0.05 — a gain of 1.04%.

The index value climbed to 1.3379 from 1.3242 with an associated index market cap of $4.028 Billion.

Company Ticker Last Change %
Advanced Cell Technology ACTC.OB $0.00 $0.00 0
Aastrom Biosciences ASTM $0.44 -$0.019 -4.14%
AVI Biopharma AVII $1.42 $0.03 2.16%
BrainStorm Cell Therapeutics BCLI.OB $0.11 -$0.005 -4.55%
CRYO-CELL International CCEL.OB $1.96 -$0.05 -2.49%
Cryo-Save CRYO.L $58.00 $0.00 0.00
Cytori Therapeutics CYTX $3.21 $0.00 0.00
Geron Corporation GERN $6.93 $0.37 5.64%
ThermoGenesis KOOL $0.67 $0.0101 1.53%
MultiCell Technologies MCET.OB $0.03 -$0.0032 -10.09%
NeoStem, Inc. NBS $1.78 $0.08 4.71%
Opexa Therapeutics Inc. OPXA $1.47 $0.06 4.26%
Osiris Therapeutics, Inc. OSIR $14.49 $0.34 2.40%
Ortec International, Inc. OTCI.OB $0.00 $0.00 0
Stem Cell Thera SSS.V $0.13 $0.005 4.17%
StemCells STEM $1.70 $0.08 4.94%

All Eyes on the Stem Cell Index Ahead of Study Results

In BUSINESS OF STEM CELLS on August 25, 2009 at 9:05 am

All Eyes on the Stem Cell Index Ahead of Study Results


After last week’s news from Geron (NADSAQ: GERN) weighed on the sector, stem cell stocks were ahead to start the week.

Geron announced early last week that U.S. health regulators put its spinal study on hold. The company’s new drug application for the treatment of subacute spinal cord injury is now under review by the Food and Drug Administration (FDA). The news dragged Geron stock down by -11% over the last week, but Merriman Curhan Ford analyst Joe Pantginis believes most of the company’s value is in its oncology program, according to Reuters.

As a whole, the Stem Cell Stocks Index is up by 2.1% today. However, it still lags the S&P 500 over the last month.

The sector’s biggest winner is Osiris Therapeutics (OSIR), which is adding 12% to its 23% five-day rally. Investors anxiously await the results of the company’s Phase III acute graft versus host disease (GvHD) study. GvHD is a deadly complication of bone marrow transfusions, which occurs in up to 60% of cases involving unrelated donors, according to HealthDay News. Patient enrollment for the study, which focuses on the company’s Prochymal as a first-line treatment for GvHD, was completed back in April.

Aastrom Biosciences (ASTM) is another top performer over the last week, up by 17%. The Ann Arbor, Michigan-based company uses stem cells and early progenitor cells from patients’ bone marrow in the production of proprietary tissue repair cell technology.

Elsewhere in the sector, one-week gains are less impressive. ThermoGenesis (KOOL) and Cytori Therapeutics (CYTX) are both up by over 4% for the period. Meanwhile, Neuralstem (CUR) moved -7% in the opposite direction.

StemCells (STEM) and Opexa Therapeutics (OPXA) have moved up and down respectively for the period, though by less than 1.5%.

As of this writing, the Stem Cell Stocks Index’s one-month performance is towards the middle of the pack among tickerspy’s more than 250 sector-based Indexes, currently up by 4.8% for the period.

Investors can follow the Stem Cell Stocks Index and view related charts and metrics at at tickerspy.com.


via tickerspy » All Eyes on the Stem Cell Index Ahead of Study Results.

WHO says embryonic treatments can’t happen?

In ALL ARTICLES on August 18, 2009 at 10:57 am
A refresher course in WHO says embryonic treatments can’t happen and the science behind why GERON really hit the wall
Did you know that the top embryonic stem cell scientists in the world have walked away from using embryos to develop treatments?
*** Embryonic research has been 100% fruitless (in regard to generating treatments) for well-funded and government supported scientists around the world for the last 11 years.
*** Dr James Thomson, father of embryonic research said about embryonic research: “…embryonic stem cells are not being used in any clinical applications yet, while alternatives such as adult stem cells figure in scores of therapies.”
*** Dr Oz said on national TV “the stem cell debate is dead,” recognizing the lack of potential in embryonic stem cells to produce cures. https://repairstemcell.wordpress.com/2009/03/31/oprah-michael-j-fox-dr-mehmet-oz-the-stem-cell-debate-is-over/
*** Ian Wilmut, who led the team that cloned Dolly the sheep, abandoned his license to attempt human cloning, saying that the researchers “may have achieved what no politician could: an end to the embryonic stem cell debate.”
*** Dr. Bernadine Healy, director of the National Institutes of Health under the first President Bush, wrote in U.S. News & World Report that these recent developments “in the first six weeks of Obama’s term, several events reinforced the notion that embryonic stem cells, once thought to hold the cure for Alzheimer’s, Parkinson’s, and diabetes, are obsolete….. In fact, adult stem cells, which occur in small quantities in organs throughout the body for natural growth and repair, have become stars despite great skepticism early on.”

via https://repairstemcell.wordpress.com/2009/05/12/only-not-on-your-life-in-america/

Obama Rocks Up Stem Cell Stocks (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL) : BioHealth Investor – Biotech and Medical Business Blog

In ALL ARTICLES, BUSINESS OF STEM CELLS on March 10, 2009 at 1:54 pm


Obama Rocks Up Stem Cell Stocks (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL) March 9, 2009

Investor alert! Be careful!  Geron went from $8 to $4 after the fiasco of their embryonic stem cell trial approval was realized.  Embryonic treatments and value are 10-20 years out!  Now, if there was an adult stem cell company or storage facility like StemSave.com … that might be worth a look! – dg

There are major gap-ups this morning in stem cell stocks after Friday evening’s news that President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding. This is supposed to be signed today, although what is interesting here is that this is not really new news other than the timing and the formality. Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.

The following prices are as of 8:19 AM EST.

Aastrom Biosciences, Inc. (NASDAQ: ASTM) +87% at $0.62

Cytori Therapeutics, Inc. (NASDAQ: CYTX) +38% at $3.20

Geron Corporation (NASDAQ: GERN) +29% at $4.99

Neostem, Inc. (AMEX: NBS)

Osiris Therapeutics, Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.

StemCells Inc. (NASDAQ: STEM) +55% at $2.15

Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57

via Obama Rocks Up Stem Cell Stocks (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL) : BioHealth Investor – Biotech and Medical Business Blog.

%d bloggers like this: